In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

Wegovy provided new insights into their effectiveness, making the choice slightly clearer. The findings? Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent.

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...